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I. INTRODUCTION

Or more narrowly stated: milk labels do.1 Between February 2007 and
April 2008, milk labeling was the subject of a Federal Trade Commission complaint,2 a Food and Drug Administration petition,3 legislation in two states,4 ad_________________________

Margaret Sova McCabe is a Professor of Law at Franklin Pierce Law Center in
Concord, New Hampshire. For thoughtful comment, encouragement, and insight, I thank my colleagues Sophie Sparrow, Chris Johnson, and Tom Field. For her capable research assistance, I am
grateful to Natalia Pence. I also thank Pierce Law for its support of my interest and work in agricultural and food law.
1.
Milk (dairy) is a highly-regulated market, primarily by the USDA, Agricultural
Marketing Service. That market‘s history is beyond the scope of this article, which focuses on
consumer demand for rBST-free milk. Readers interested in U.S. dairy regulation will find helpful
information at http://www.ams.usda.gov.
2.
Complaint at 1, FDA Matter No. 072-3480 (Feb. 27, 2007), available at http://www.
ftc.gov/os/comments/monsanto/070227letterMonsantorBST.pdf.
3.
Petition for Labeling of Products Produced with Posilac, FDA Docket No. 2007P0059 (Feb. 20, 2007), available at http://www.regulations.gov/fdmspublic/component/main?main=
DocumentDetails=FDA-2007-P-0119-0002.

475

Reprinted from the Drake Journal of Agricultural Law. Copyright is retained by Drake University.
File: McCabe MACRO Final.doc

476

Created on: 11/16/2008 11:45:00 AM

Drake Journal of Agricultural Law

Last Printed: 1/3/2009 12:21:00 PM

[Vol. 13

ministrative rulemaking in two,5 and a federal district court action.6 All of these
activities focused on how much information the consumer should have about the
use of recombinant bovine somatotropin7 (rBST) in dairy herds and how that
information is conveyed to milk consumers. rBST is a hormone that increases
milk production used in dairy cows producing milk for human consumption.8
Some consumers believe rBST poses human health risks; others believe it harms
cows; others want to avoid genetically modified material, while some consumers
do not care about rBST at all.
Why is rBST controversial? For two main reasons: 1) it is a genetically
engineered hormone and 2) it poses health risks to cows treated with it.9 Many
consumers fear genetically engineered materials in foods because they believe
there is not enough known about how modifying a food‘s genes will impact human and environmental health.10 Setting aside whether consumers‘ fears are rational, these fears are not shared by the FDA. The FDA first presumed genetically engineered foods ―generally regarded as safe‖ under the Food, Drug, and
Cosmetics Act, but later required a premarket clearance procedure – both
schemes permitting genetically engineered foods into the food supply without a
mandatory disclosure label.11 The genetically engineered foods issue has multiple layers – do they harm humans? Our environment? Animals? Since there are
few definitive answers to these questions, other than studies confirming safety,
consumers‘ fears are driven by the unknown.
4.

S.B. 595, 2008 Sess. (Kan. 2008); H.B. 1300, 115th Gen. Assem. 2d Reg. Sess. (Ind.

2008).
5.
Pa. Dep‘t of Agric.: Milk Labeling Standards, 2.0.1.17.08 (Jan. 17, 2008); Ohio
Emergency Rule, Dairy Labeling, 901:11-8.01 (May 22, 2008).
6.
Complaint at 1, Int‘l Dairy Foods Ass‘n v. Boggs, No. 08-cv-00628-JLG-NMK
(E.D. Ohio filed July 7, 2008).
7.
rBST is a synthetic hormone that increases milk production by as much as 20%.
Bradford L. Barham & Jeremy Foltz, rBST Adoption in the United States: That Was the Juggernaut…That Wasn’t 17 CHOICES 15, 16 (Summer 2002). rBST is manufactured only by Monsanto
and is marketed under the trade name Posilac. Readers should note that Monsanto sets milk production increases at 10-15%. See BST by Posilac, http://www.monsantodairy.com/about/index.html
(last visited Nov. 1, 2008).
8.
Robert Collier, Regulation of rBST in the US, 3 AGBIOFORUM 156 (2000).
9.
Id. at 159.
10.
See generally Mariella Nocenzi et al., Genetic Modified Organisms: Confronting
Needs, Interests, Responsibilities and Fears, 15 INT‘L REV. SOC. 305 (2005); for one consumer
perspective and an anti-genetic engineering view see ANDREW KIMBRELL, YOUR RIGHT TO KNOW:
GENETIC ENGINEERING AND THE SECRET CHANGES IN YOUR FOOD (2007).
11.
Statement of Policy: Foods Derived from New Plant Verities, 57 Fed. Reg. 22,984
(May 29, 1992); Proposed Rules: Premarket Notice Concerning Bioengineered Foods, 66 Fed.
Reg. 4706 (Jan. 18, 2001). See also Alliance for Bio-Integrity v. Shalala, 116 F. Supp. 2d 166, 170
(D.D.C. 2000).
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The rBST science shows negative side effects on dairy herds. Specifically, Monsanto‘s safety studies showed an increased risk of mastitis, twinning
rates, and injection site infections.12 Yet, the law does not require zero risk to
animals when approving a new veterinary drug.13 Despite little scientific evidence that genetically engineered foods are unsafe and a legally tolerable risk to
animals, many consumers still reject rBST as unnatural, unsafe, and undesirable.
Since many consumers avoid rBST, why would farmers use it? Simply
put, it increases milk production.14 Theoretically, a more productive dairy is a
more profitable one. rBST is also an innovation and is attractive to farmers who
want to be competitive. Finally, farmers use it because Monsanto markets it to
them. As any company with a potentially profitable product should, Monsanto
has sold many farmers on the benefits of rBST.15
Today‘s dairy farmers face a complex industry – consolidation and organic production force difficult economic choices. Milk consumers also face
difficult choices – conventional? hormone free? organic? What do these labels
mean about the choices farmer‘s make when producing the milk? These questions and choices exist because of the FDA‘s 1993 approval of rBST.16 Since that
approval, the dairy industry and consumers have struggled with the consequences
of rBST milk in the marketplace.
The current skirmishes over the use of the genetically engineered hormone in US dairy herds are important. Ultimately, the controversy is about marketing. Realistically, consumers already have rBST information on milk labels.17
rBST-free milk carries the statement ―from cows not treated with rBST,‖ followed by the disclaimer ―no significant difference has been shown between milk
derived from rBST-treated and non-rBST treated cows.‖18 However, some producers also add claims such as ―no added hormones‖ or ―artificial hormone
free.‖19 These claims and deviations from the FDA guidelines area are what upset Monsanto, farmers who use rBST, and producers. They believe that the unsanctioned claims mislead consumers into believing that rBST-free milk is supe_________________________
12.
Stauber v. Shalala, 895 F. Supp. 1178, 1183-84 (W.D. Wis. 1995).
13.
Id. at 1191 (The FDA determined that the risk to animals was ―manageable‖—
meaning that through appropriate farming techniques the farmers could manage side effects on the
cows).
14.
Barham & Foltz, supra note 7, at 15.
15.
See id.
16.
See Interim Guidance on the Voluntary Labeling of Milk and Milk Products from
Cows That Have Not Been Treated with Recombiant Bovine Somatotropin, 59 Fed. Reg. 6279
(Feb. 10, 1994).
17.
See id. at 6280.
18.
Id.
19.
Complaint, FDA Matter No. 072-3080, supra note 2, at 1, 9.
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rior or more healthful.20 They are right: this is exactly what consumers seeking
out rBST-free milk believe – or what media outlets who cover the issue want the
public to believe.21
Early predictions were that consumers would adjust to rBST in milk, but
the opposite is true. While it took nearly fifteen years for a clear consumer preference for rBST-free milk to emerge in the marketplace – 2008 marked the year
that it did. Most milk producers‘ labels adhere to the FDA guidance, including
the disclaimer. However, this information has made little difference to consumers.22 Quite the opposite is true: consumers express a preference for rBST-free
milk raising the important question: Why haven‘t consumers embraced the
FDA‘s rBST safety ruling? The probable reason is that consumers distrust that
safety ruling. The primary reason for the distrust is that rBST is genetically modified and does pose some health risk to animals.
Thus, the current controversy pits consumers against producers, unproven safety concerns against regulatory approval of rBST, and tradition against
innovation. There are three things that the industry, consumers, and lawmakers
could do to solve this problem. These three things are: 1) conduct consumer
surveys determining the true extent of consumer confusion and consumer preference; 2) conduct consumer research to determine the most effective milk labels
at providing consumer information; and 3) based on the consumer research of the
previous two suggestions, make a decision to promote USDA organic milk as the
one solution for consumers who want rBST-free milk or devise a symbol, similar
to the USDA organic symbol, that represents rBST-free milk. Unless the parties
engage in solutions like these, the controversy will continue.
II. WHY DO CONSUMERS CARE? A SHORT HISTORY OF RBST, 1987-2007
Controversy surrounded rBST from the time Monsanto first applied for it
as a new animal drug in 1987.23 Many consumers recoiled at the thought of a
genetically engineered hormone24 being injected into cows to increase milk pro_________________________
20.
Id. at 1.
21.
An internet search for ―rBST‖ results in a plethora of websites that decry rBST use
and highlight its ―dangers.‖ However, there are no widely publicized consumer studies that indicate what consumers know or believe about rBST. See id. at 4-5.
22.
See, e.g., Caren Wilcox, Growth and Challenges Await Organic Dairy, 109 DAIRY
FOODS 114 (2008).
23.
See Collier, supra note 8, at 156. See also 21 U.S.C. § 360b (2006) (mandating new
animal drugs must be approved by the FDA).
24.
The history of consumer reaction to genetically modified foods is beyond the scope
of this article, though I believe that the FDA‘s early presumption that genetically engineered foods
are ―Generally Regarded As Safe‖ (GRAS) under the Food, Drug, and Cosmetics Act, 21 U.S.C. §
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duction, even though rBST is indistinguishable in the lab from its natural counterpart, BST.25 Today, consumers‘ concerns about rBST include increased use of
antibiotics in dairy herds to reduce rBST side effects and animal welfare issues.
Analysts in the area also often note that the United States is one of the few nations to approve rBST use, with Canada, New Zealand, and Australia banning it,
and the European Union continuing to restrict its use.26
A. 1987 – 1994: FDA Approval
BST is a naturally occurring hormone.27 Scientists discovered that injections of BST increased milk production as early as the 1930s, though BST production was impractical.28 This changed through the 1970s and early 80s, when
Genentech and Monsanto developed genetically engineered BST – rBST – commercially known as Posilac.29 In 1987, Monsanto applied to the FDA for Posilac
approval.30 Although there were some side effects for cows, such as increased
incidence of twins, injection site infections, and a slight increase of mastitis, the
FDA ruled the ―risks to animal health were not significant‖ and approved Posilac‘s use in cows.31 Because of that decision, today farmers inject cows with
rBST to increase their milk production.32

321(s) (2006), and subsequent premarket clearance procedure is linked to continued consumer
concerns about rBST. For further reading on the topic, see generally Alliance for Bio-Integrity v.
Shalala, 116 F. Supp. 2d 166, 166 (D.D.C. 2000); Statement of Policy: Foods Derived from Plant
Varieties, 57 Fed. Reg. 22,984 (May 29, 2001); Mario Teisel et al., Focus Group Reactions to
Genetically Modified Food Labels, 5 AGBIOFORUM 6 (2002); Nocenzi, et al., supra note 10;
KIMBRELL, supra note 10.
25.
John F. Murphy, Mandatory Labeling of Food Made from Cloned Animals: Grappling with Moral Objections to the Production of Safe Products, 63 FOOD & DRUG L.J. 131, 140-41
(2008) (analogizing consumer concerns about cloned meat to rBST controversy and noting the
rBST controversy ―is another poignant example that American consumers have come to care about
not just merely what is on their plate (or in their glasses), but also how it got there.‖). See also Lars
Noah, Managing Biotechnology’s [R]evolution: Has Guarded Enthusiasm Become Benign Neglect? 11 VA. J.L. & TECH. 4, 40 n.144 (2006) (reviewing history of rBST approval).
26.
See Dirk Brinkman, The Regulation of rBST: The European Case, 3 AGBIOFORUM
164 (2000); Kevin Jones, Constructing rBST in Canada: Biotechnology, Instability and the Management of Nature, 25 CAN. J. SOC., 311, 311-41 (2000).
27.
Collier, supra note 8, at 157 (noting that until Monsanto and Genentech discovered
how to genetically engineer BST, its commercial production was impractical).
28.
Id. at 156.
29.
Id.
30.
Id.
31.
Stauber v. Shalala, 895 F.Supp. 1178, 1184 (W.D. Wis. 1995).
32.
Barham & Foltz, supra note 7, at 15.
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FDA approval of Posilac was politically and legally controversial.33 Before the approval was issued, Senator Patrick Leahy of Vermont requested and
obtained a General Accounting Office (GAO) investigation of FDA actions.34
The GAO recommended that the FDA withhold approval of Posilac pending further research of its ―potential negative impact on human health.‖35 Next, Congress delayed the sale of the drug for 90 days while ―an inter-agency task force
supervised by the Office of the President reviewed the data upon which the FDA
based its decision.36 By January 1994, that task force concluded the ―FDA‘s. . .
[decision] was adequately supported,‖ by evidence, and that Monsanto could
begin marketing Posilac to dairy farmers.37
B. 1995, Challenging the Science: Stauber v. Shalala
The FDA‘s rBST approval methodology and the science behind it survived judicial review in 1995.38 Consumers brought the action seeking declaratory and injunctive relief against the FDA and seeking to prevent rBST from entering the human food supply.39 Specifically, the consumer-plaintiffs made claims
under the Food, Drug, and Cosmetic Act, the Environmental Protection Act, and
the Administrative Procedure Act.40 The government prevailed at summary
judgment, primarily because the plaintiffs had no admissible, relevant evidence
to support their claims because they relied on material never presented to the
FDA during the Posilac approval process.41
The consumer claims echoed those raised by the political process and
GAO investigation: the FDA did not adequately consider health and safety
claims, mandatory warning labels should have been required on Posilac packaging to highlight its negative side effects on the animals, and the government
_________________________
33.
See Nocenzi et al., supra note 10. See also KIMBRELL, supra note 10. The history of
the controversy is beyond the scope of this article, though it is very interesting. rBST is considered
the ―first‖ genetically modified substance allowed for human consumption under the FDA‘s policy
of presumptive safety. Since milk is a cornerstone of American nutrition, especially for children,
there was likely no worse choice than milk to forge the way for genetically engineered foods.
34.
Collier, supra note 8, at 158.
35.
Stauber, 895 F. Supp. at 1183.
36.
Id.
37.
Id. See also Animal Drugs, Feeds, and Related Products; Sterile Sometribove Zinc
Suspension, 58 Fed. Reg. 59,946 (Nov. 12, 1993) (codified at 21 C.F.R. pts. 510 and 522). The
actual approval date was 1993, but the Congressional moratorium on rBST‘s sale did not expire
until Feb. 3, 1994.
38.
See Stauber, 895 F. Supp. at 1178.
39.
Id. at 1182-83.
40.
Id. at 1182.
41.
Id. at 1183.
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should have conducted an environmental impact statement before approving Posilac.42 The government‘s position was simply that it complied with the relevant
law and rules when approving rBST.43
The Stauber decision revealed some unpleasant realities about milk production to the public. The first concern, which remains one of the biggest today,
is that use of rBST also increases the use of antibiotics. Cows then secrete those
antibiotics into milk sent to market. Increased human consumption of antibiotics
does lead to increased antibiotic resistance in humans.44 For example, in 2005,
the FDA withdrew the use of the antibiotic Baytril in poultry destined for human
consumption out of concern that humans would develop resistance to one of the
few drugs effective against biological terrorism materials.45 Consumers avoid
rBST milk for similar reasons – they are concerned that they are drinking antibiotics with their milk, and they may be right.
rBST-treated cows are often treated with antibiotics to prevent or treat
the mastitis that can be more frequent in treated cows. In Stauber, the plaintiffs
asserted this was a valid safety concern, but the court was not swayed.46 Instead,
it ruled that the FDA did not rely arbitrarily or capriciously on the USDA milk
grade testing process to screen out milk that had excessive antibiotic residue.47
However, the court also acknowledged that, at the time, there were limitations on
the testing.48 Though the Grade A pasteurized milk standard was rigorous, testing at the time was only for the four most common antibiotics used in dairy
herds.49 The court acknowledged that over fifty drugs were used to treat cow
infections, some of them not even approved for use in cows.50 Therefore, unless a
farmer treating with rBST and antibiotics used one of the four antibiotics tested
for, consumers could unwittingly drink antibiotic residue from one of the other
forty-six drugs used but not tested for.
_________________________
42.
43.
44.

Id. at 1182.
Id.
See FDA, FINAL DECISION OF THE COMMISSIONER, NO. 2000N-1571, WITHDRAWAL
OF APPROVAL OF THE NEW ANIMAL DRUG FOR ENROFLOXACIN IN POULTRY 53 (2005), available at
http://www.fda.gov/oc/antimicrobial/baytril.html. (Baytril is the trade name for Enrofloxacin, a
fluoroquinolone. Humans are treated with a similar drug named Cipro). See also Enrofloxacin for
Poultry; Final Decision on Withdrawal of New Animal Drug Application Following Formal Evidentiary Public Hearing; Availability, 70 Fed. Reg. 44,105 (Aug. 1, 2005).
45.
See id; Ellen K. Sibergeld & Polly Walker, What if Cipro Stopped Working, N.Y.
TIMES, Nov. 3, 2001, at A23.
46.
Stauber, 895 F. Supp. at 1192.
47.
Id.
48.
Id.
49.
Id.
50.
Id. at 1184.

Reprinted from the Drake Journal of Agricultural Law. Copyright is retained by Drake University.
File: McCabe MACRO Final.doc

482

Created on: 11/16/2008 11:45:00 AM

Drake Journal of Agricultural Law

Last Printed: 1/3/2009 12:21:00 PM

[Vol. 13

Indeed the court acknowledged ―[b]ecause the current regulatory scheme
does not detect the presence of all drug residues in dairy products, there is a risk
that greater amounts of antibiotic drug residue will be ingested by human dairy
consumers.‖51 This is not exactly reassuring for the dairy consuming public, yet
it illustrates the weakness of the consumers‘ case: they could not produce evidence to support their health and safety concerns. Even more damaging to consumers‘ claims was the fact that there was no long-term study of whether antibiotics in milk affected human health at all.52
The court also touched on other specific differences in rBST milk that
consumers claimed were significant, yet the FDA ruled immaterial.53 Specific
consumer concerns were: higher somatic cell (white blood cell) counts in milk
and higher insulin growth factor (IGF-1) levels.54 In both cases, the court found
no evidence to support the consumers‘ claims.55 Since the FDA had reviewed
Monsanto‘s studies on somatic cell count that showed no significant increase in
the rBST milk, the Court ruled the FDA had done its job.56 As for IGF-1, since
Monsanto had not done any studies on human health but could present evidence
that there was no impact on the digestive tract in a two-week rat study, the court
found the FDA had also acted reasonably on this issue.57
Stauber upheld the FDA‘s approval of Posilac, though it is reasonable to
conclude that the court could do little more given the standard of review and the
fact that the plaintiffs‘ evidence had not been reviewed during the FDA approval
process. The court considered only whether the FDA had acted arbitrarily or
capriciously, abused its discretion, or otherwise acted outside the law.58 Given the
close scrutiny that the rBST approval process had already survived, including the
GAO review, it is difficult to imagine any other ruling. In fact, the true issue was
science – or more accurately stated, the lack thereof. This is especially so because the FDA has scientific expertise, entitling its evaluation of the science to
great deference by the court.59
The plaintiffs did submit scientific evidence to the Stauber court.60 The
problem was that the same evidence had not been presented to the FDA during
_________________________
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.

Id. at 1185.
Id.
Id.
Id. at 1185, 1193.
Id.
Id.
Id. at 1185.
Id. at 1189 (citing Upjohn Mfg. v. Schweiker, 681 F.2d 480, 483 (6th Cir. 1982)).
See id. (discussing deference afforded agency decisions).
Id. at 1190.
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the drug review and thus could not be considered by the court.61 As a result, the
Court found that the FDA‘s process was sound, even when it decided to rely on
testing process for grading milk to make sure antibiotic residue was kept out of
the milk supply.62 The Stauber case raises many unsettling points about what was
truly known about rBST and its effect on humans when it was approved.
However, the fact is that rBST has been on the market for almost fifteen
years without consumers returning to convince the FDA that it was wrong when
it found rBST ―has no significant effect on the overall composition of milk.‖63
Since the FDA concluded that there was no compositional difference between
milk from rBST treated cows and those that are not, there is no legal basis for the
FDA to label the milk.64 As Stauber recognized ―the FDA does consider consumer opinion relevant when determining whether a label is required to disclose
a material fact.‖65 As a result, absent scientific proof that rBST milk is materially
different from rBST-free milk, consumers have no right to know whether it has
been used to produce milk, as Vermont found in 1996.66
C. 1996 Commercial Speech (Round One): Int‘l Dairy Foods Ass‘n v. Amestoy
Posilac‘s next challenge came from Vermont‘s law mandating disclosure
of rBST use on the milk label or on the grocery store shelf.67 The Vermont regulation mandated a sign at the dairy case stating:
The products in this case that contain or may contain milk from rBST-treated cows
either (1) state on the package that rBST has been or may have been used, or (2) are
identified by a blue shelf label like this [blue rectangle], or (3) a blue sticker on the
package like this [blue dot].68

Dairy producers, represented by the International Dairy Foods Association, moved for a preliminary injunction against implementing the law, which the
district court denied finding there was no irreparable harm to dairy producers.69
Overruling the district court, the Second Circuit rejected the law for many of the

_________________________
61.
62.
63.
64.
65.
66.
67.
68.
69.

Id.
Id. at 1192.
Id. at 1193.
Id.
Id.
See Int‘l Dairy Foods Ass‘n v. Amestoy, 92 F.3d 67, 74 (2d Cir. 1996).
Id. at 69-70.
Id. at 70.
Id.
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same reasons Stauber upheld FDA‘s approval – there was simply no scientific
evidence of material difference in the record, regardless of consumer concerns.70
Vermont‘s statute requiring farmers to label milk from rBST-treated
cows illustrates the strength of consumer concern in Vermont,71 but the proconsumer statute was simply an unconstitutional restriction on commercial
speech. Specifically, the Second Circuit held that consumer interest alone was
insufficient to allow regulation of commercial speech under Central Hudson.72
When striking down the law, the court ruled that if consumer interest alone were
enough, ―there is no end to the information that states could require manufacturers to disclose about their production methods.‖73
The district court originally upheld Vermont‘s mandatory disclosure law,
reasoning that there was no irreparable harm to the producers based primarily on
the economic impact of the labels.74 The Second Circuit found fault with this
economic analysis primarily because the law caused irreparable harm by requiring producers to make an involuntary statement, though true, in order to offer
their products for sale (regardless of economic impact).75 However, the most
instructive part of the case is the court‘s ruling that the Vermont law failed the
Central Hudson standard because the state lacked a substantial interest.76 Despite
the political controversy over rBST prior to FDA approval, the court emphasized
that producers could not be required to disclose its use in cows absent ―reasonable concern for human health or safety or some other sufficiently substantial government concern.‖77 The court left it to ―those consumers interested in such information [to] exercise the power of their purses by buying products from manufacturers who voluntarily reveal it.‖78 However, when the court left consumers to
_________________________
70.
Id. at 74.
71.
Id. at 69.
72.
Id. at 74; see also Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm‘n of N.Y.,
447 U.S. 557, 566 (1980) (―In commercial speech cases, then, a four-part analysis has developed.
At the outset, we must determine whether the expression is protected by the First Amendment. For
commercial speech to come within that provision, it at least must concern lawful activity and not be
misleading. Next, we ask whether the asserted governmental interest is substantial. If both inquiries
yield positive answers, we must determine whether the regulation directly advances the governmental interest asserted, and whether it is not more extensive than is necessary to serve that interest.‖).
73.
Int‘l Dairy Foods Ass‘n v. Amestoy, 92 F.3d 67, 74 (2d Cir. 1996) This position
may not take into account the role of preemption in manufactured food-labeling requirements under
the FDCA.
74.
Id. at 70-71.
75.
See id. at 71.
76.
Id. at 73.
77.
Id. at 74.
78.
Id.
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the power of their purses, it left regulators to consider how consumers exercise
that power. As the court wrote, ―consumer curiosity alone is not a strong enough
state interest to sustain the compulsion of even an accurate, factual statement.‖79
Where does this leave the consumer who is skeptical of rBST safety and curious
enough to continue reading labels? It leaves her with voluntary disclosure, which
remains at the heart of the controversy today.
D. 1994 to Present: Producers Safe Harbor – FDA Milk Label Guidance
What can producers voluntarily reveal about rBST-free milk on labels?
In 1994, the FDA labeling guidelines advised manufacturers who label milk
―from cows not treated with rBST‖ to include the disclaimer with the statement
that ―‗No significant difference has been shown between milk derived from
rbST-treated and non-rbST-treated cows.‘‖80 The FDA label guidance is
straightforward and intended to protect against consumers having the impression
that rBST-free milk is superior or more nutritious than milk from cows treated
with rBST.
The FDA‘s notice clearly stated that it was not binding on the FDA or
any state, nor did it create any rights for individuals.81 The guidance was simply
the FDA‘s interpretation of the law and it reserved the right to change its interpretation should it receive compelling comments.82 The guidance contains relevant advice to the current label controversy when it counsels: ―States should
evaluate any labeling statement about rBST in the context of the complete label
and all labeling for the product, as well as any advertising for the product.
Available data on consumers‘ perceptions of the label statements could also be
used to determine whether a statement is misleading.‖83
The guidance also suggested ways that states could insure that claims
were valid – such as recordkeeping by producers or third party certification.84
Today, the 1994 guidance remains the same. Its purpose also remains the same –

_________________________
79.
Id. (citing Riley v. Nat‘l Fed. of the Blind, 487 U.S. 781, 797-98 (1988)).
80.
Interim Guidance on the Voluntary Labeling of Milk and Milk Products from Cows
that Have Not Been Treated with Recombinant Bovine Somatotropin, 59 Fed. Reg. 6279, 6280
(Feb. 10, 1994) (providing guidance to dairy industry with the intent to preclude ―rBST-free labels‖
from giving consumers the impression that milk from rBST treated cows is somehow unsafe or less
healthful than rBST-free).
81.
Id.
82.
Id.
83.
Id.
84.
Id.
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to support the legally valid conclusion that there is no material difference between milk from rBST treated cows and milk from those that are not.85
Despite the label requirement meant to inform consumers that there is no
difference between rBST-free and conventional milk, in 2007, several major
dairy marketers informed producers that they would no longer accept milk from
cows treated with rBST.86 Marketers took the action because consumers were
demanding ―hormone free‖ milk, but ―they will not accept any price increases for
this milk.‖87 This is not a small consumer movement. Large distributors such as
Publix and Kroger announced that their store brand milk would be hormonefree.88
E. 2006 -2008, The rBST-free Market Emerges
The market demand for rBST-free milk has consequences for farmers. In
one case, a state tried to use milk price controls to protect farmers who use
rBST.89 In 2006, the New Jersey Department of Agriculture attempted to fix a
milk price premium for rBST-free milk.90 Specifically, processors were demanding rBST-free milk from farmers without agreeing to pay farmers voluntary premiums. As a result, farmers using rBST had a choice: either abandon it with
reduced production or continue to use it and accept a lower price for the milk.91
At the premium‘s public hearing, one farmer relied on a Monsanto produced
pamphlet to testify that there was a ―hypothetical loss‖ of $0.76 per hundredweight for rBST-free milk.92 Based in part on that testimony, the Director made
the following findings:
_________________________
85.
Id.
86.
DairyBusiness Communications, Dairy Technology Restrictions Move Toward
Deadlines, VOICES FOR CHOICES, July 31, 2007, at 4, available at http://www.dairybusiness.com/
voicesforchoices/pdf/vfe-newsletter-7.31.pdf.
87.
Id.
88.
Id.; Kroger Rejects GMO Milk: The Tipping Point, ENVIRONMENTAL NEWS
NETWORK, Aug. 7, 2007, available at http://www. enn.com/agriculture/article/21413/print.
89.
See generally In re Sept. 28, 2006 Order of Dir. of the Div. of Mktg. and Dev., No.
A-827-06T1, 2006 WL 3783503 (N.J. Super. Ct. App. Div. Dec. 27, 2006).
90.
Id. at *1.
91.
Id. at *2. For example, a year after the New Jersey case, the American Farm Bureau
Federation Quarterly Marketbasket Survey for the second quarter of 2007 indicated three levels of
pricing for wholesale milk ½ gallons: regular whole, $2.22; rBST-free $3.01; organic $3.65. DairyBusiness Communications, ‘Niche Market’ Milk Drawing Premium Price, VOICES FOR CHOICES,
July 31, 2007, at 1, available at http://www.dairybusiness.com/voicesforchoices/pdf/VfCnewsletter-7.31.pdf.
92.
In re Sept. 28, 2006 Order of Dir. Of the Div. of Mktg. and Dev., No. A-827-06T1,
at *3.

Reprinted from the Drake Journal of Agricultural Law. Copyright is retained by Drake University.
File: McCabe MACRO Final.doc

2008]

Created on: 11/16/2008 11:45:00 AM

Last Printed: 1/3/2009 12:21:00 PM

Do Milk Labels Accurately Inform Consumers About rBST?

487

Posilac results in increased milk production; the processors demand ―rBST-free‖
milk; negotiations over premiums for ―rBST-free milk‖ were difficult; and ―rBSTfree‖ milk is a value added product. . . .[A] processor demanding ―rBST-free‖ milk
should be obligated to cover at least the costs of production.93

Based on these findings, the Director did impose a $0.76 per hundredweight
premium for rBST free milk.94 On appeal, the court vacated the premium because the Director‘s decision rested on hypothetical, not actual, data.95 However,
the Court did not preclude the Director from conducting additional hearings on
premiums for ―rBST-free‖ milk.96
New Jersey did hold additional hearings. In late 2007 and early 2008,
the Director held hearings on both a fuel premium and the rBST premium.97 He
concluded that there ―is evidence on either side of the issue of whether an rBST
premium should be imposed.‖98 Since the evidence could not clearly establish
whether rBST-free milk was a value added product that warranted a price premium, the Director declined to impose one.99 Rather, because of the inadequate
evidence, he decided it was not an appropriate time to interfere with the market.100
Despite the FDA‘s position on rBST‘s safety, consumer demand for
rBST- free milk currently drives the market. There is also growing evidence that,
despite the FDA‘s ―no material difference‖ stance, how milk is produced plays a
key role in its nutritional quality. For example, in June 2008 a published study
showed that organic and low-input organic milk had higher levels of key nutrients. 101 Though the study did not specifically examine rBST use, many con_________________________
93.
Id. at *4.
94.
Id.
95.
Id. at *6.
96.
Id. at *7.
97.
Letter from Alfred Murray, Dir., Div. of Mktg. & Dev., NJ Dept. of Agric. Mkts. &
Dev. to Nina Mitchell Wells, Sec‘y of State, at 1 (April 10, 2008).
98.
Id.
99.
Id. at 1-2.
100.
Id.
101.
Gillian Butler et al., Fatty Acid and Fat-Soluble Antioxidant Concentrations in Milk
from High-and Low-Input Conventional and Organic Systems: Seasonal Variation, 88 J. SCI. FOOD
AGRIC. 1431 (2008). The study compared dairy operations in the United Kingdom using either
high-input or low-input organic farming methods. Low-input and organic milk had higher nutrient
quality, including beneficial fatty acids. High-input methods resulted in fewer key nutrients, even
in cases where the herd was supplemented with vitamins. Specifically, high-input operations supplementing with Vitamin E did not produce milk with higher levels of Vitamin than low-input
operations not supplementing. It is important to note that this study does not examine rBST, but I
have little doubt that it will be used to support the argument that ―naturally‖ produced milk is superior, including arguments against rBST.
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sumers will undoubtedly interpret its findings to supporting their sentiment that
rBST-free milk is superior because it is more natural.
III. FALSE AND MISLEADING? FEDERAL TRADE COMMISSION ACTIONS
In 2007, several dairies‘ interpretation of the FDA guidance led Monsanto to complain to the Federal Trade Commission that the rBST-free labeling used
in many markets misleads consumers.102 This was not Monsanto‘s first effort to
curb rBST-free labeling.103 In 2003, Monsanto challenged Oakhurst Dairy over
its labels claiming ―No Artificial Growth Hormones‖ in federal court.104 In 2007,
Monsanto and various dairy producers complained to the FTC that those producers making claims such as ―cows are not injected with BST (hormones)‖ and
―The Natural Milk – No Added BST (hormones)‖ were misleading consumers
because the labels conflicted with the FDA labeling guidance.105 The complaint
maintains that statements about hormone-free milk mislead the consumer into
believing that milk from cows not treated with rBST is superior or more nutritious.106
Monsanto‘s FTC complaint was right in one significant way – many consumers believe that milk from rBST free cows is more desirable (or there would
not be a market for the milk).107 Whether this is a result of the marketing practices complained of by Monsanto to the FTC – or whether it is the persistence of
the consumer concerns in existence since rBST was approved is unknown. However, this consumer preference should signal label regulators that consumers do
not believe the FDA rBST safety ruling.

_________________________
102.
Complaint, FDA Matter, No. 072-3080, surpa note 2 at 1.
103.
Petition for Plaintiff at 1, Monsanto Co. v. Oakhurst Dairy, No. 03-11273 (D. Mass.
filed July 3, 2003).
104.
Id.
105.
See Complaint, FDA Matter No. 072-3080, supra note 2, at 5.
106.
See id. See also Butler, supra note 101, at 1435. It is significant to note that in June
2008, a study was published showing that the nutritional value of organic milk and low-input nonorganic milk was higher than conventional. Certainly, this study while not specifically identifying
rBST as unsafe, will add to consumer sentiment that rBST free milk is indeed superior. But see,
DairyBusiness Communications, A Fair Question: Who Is Asking for rBST-free Milk?, VOICES FOR
CHOICES, Sept. 25, 2007, at 4, available at http://www.dairybusiness.com/voicesforchoices/pdf/
VfC.9.25.pdf (questioning whether consumers really care about rBST in milk).
107.
See Dairy Business Communications, ‘Niche Market’ Milk Drawing Premium Price,
VOICES FOR CHOICES, July 31, 2007, at 1 available at http://www.dairybusiness.com/voicesfor
choices/pdf/VfC-newsletter-7.31.pdf.
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On August 21, 2007, the FTC responded to the Monsanto request for action against false and misleading rBST labels.108 The FTC noted that Monsanto
was aware that the milk producers had the right to inform consumers about
whether the milk was produced using rBST or not.109 Further, the FTC informed
Monsanto that it had independently reviewed websites and other marketing in
light of the 1994 FDA Guidance and with FDA staff.110 The FTC concurred with
the FDA policy that producers could label rBST-free, as long as ―in the context
of the entire label, they do not mislead consumers to believe that milk from cows
not treated with rBST is safer or of higher quality.‖111 The FTC‘s response letter
also acknowledges that there may be reasons that producers want to advertise as
rBST- free other than safety or quality – and that it is permissible so long as consumers are not misled. The primary example of ―other reasons‖ is animal welfare.
Ultimately, the FTC ruled that its staff ―did not find any examples of national or significant regional advertising campaigns that made express or implied
claims linking rBST to human health or safety.‖112 While the FTC did note some
unfounded rBST claims, it advised companies engaging in such claims to revise
their marketing.113 Given that the companies appeared cooperative and there was
no evidence of widespread consumer confusion, the FTC declined action.114
In order to understand better the FTC‘s decision, a slight digression is
appropriate. In 2008, Sanderson Farms sued Tyson Foods for misleading consumers with its ―Raised without Antibiotics Claim‖ used on Tyson‘s chicken.115
That claim carried the qualifying language ―that impact antibiotic resistance in
humans.‖116 The marketing claim was a phenomenal success, with two problems
– it was not USDA approved, nor was it accurate.117 While the Tyson‘s farmers
may have ―raised‖ chicks without antibiotics, Tyson‘s label did not disclose the
fact that while in their shells chicks were injected with antibiotics and later fed a
type of antibiotic known as ionophores.118 Additionally, the no antibiotics
claim‘s qualifying language ―that impact antibiotic resistance in humans‖ had no
_________________________
108.
See Letter from Mary K. Engle, Assoc. Dir., Div. of Adver. Practices, FTC, to Jodie
Z. Bernstein, Esq., Dana B. Rosenfeld, Esq., Bryan Cave L.L.P. (Aug. 21, 2007), available at
http://www.ftc.gov/os/closings/staff/070821monsanto.pdf.
109.
Id.
110.
Id.
111.
Id.
112.
Id.
113.
Id.
114.
See id.
115.
Sanderson Farms v. Tyson Foods, Inc., 547 F. Supp. 2d 491, 492 (D. Md. 2008).
116.
Id.
117.
Id. at 494.
118.
Id. at 492.

Reprinted from the Drake Journal of Agricultural Law. Copyright is retained by Drake University.
File: McCabe MACRO Final.doc

490

Created on: 11/16/2008 11:45:00 AM

Drake Journal of Agricultural Law

Last Printed: 1/3/2009 12:21:00 PM

[Vol. 13

significant meaning to consumers.119 As a result, the court ruled that the label
claims were literally false.120
To prove their case, Sanderson and its co-plaintiff Perdue presented significant evidence of consumer confusion to the court.121 Specifically, the court
relied on the various consumer survey methodologies employed by the plaintiffs‘
experts when ruling the labels were misleading.122 Experts found 63.4% of survey respondents thought the label claim meant no antibiotics had been used
(when they had), and that 54.9% of consumers disregarded the qualifying language ―that impact antibiotic resistance in humans.‖123 These statistics, and the
testimony of Tyson‘s own expert that ―these figures far exceed the level of consumer survey evidence usually required by courts‖ to establish a Lanham Act
violation, lead the court to rule in favor of the plaintiffs.124
When issuing the injunction and putting an end to the labels, the court
wrote:
Having heard testimony for four days and having reviewed hundreds of exhibits,
this Court is convinced by a preponderance of the evidence that a substantial percentage of consumers are misled by Defendant‘s advertisements carrying the message
―Raised Without Antibiotics that impact antibiotic resistance in humans.‖ The qualifying language does not appear to serve its intended purpose-the consumer is still
led to believe that Defendant does not use antibiotics, when in fact Defendant uses
ionophores in its chicken feed and injects its chicken eggs with antibiotics. Indeed,
the qualification may only serve to reinforce that Defendant‘s chicken is ―Raised
Without Antibiotics,‖ a claim that is literally false. 125

This digression is relevant to rBST because, throughout the years of
claims of consumer confusion on both sides, no proceeding has produced the
type of survey evidence that was so compelling in the Tyson case. In order to
resolve the rBST controversy, such data will be not only helpful, but essential.
IV. SAFE OR NOT? FOOD AND DRUG ADMINISTRATION PETITION
Just 12 days before Monsanto and producers complained to the FTC
about the unfair marketing practices, the FDA received a petition seeking the
withdrawal of Posilac‘s approval or action requiring a cancer risk-warning label
_________________________
119.
120.
121.
122.
123.
124.
125.

Id. at 505.
Id.
Id. at 499-502.
Id. at 502-03.
Id. at 504.
Id.
Id. at 505.
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on milk from rBST treated cows.126 The petitioners are the Cancer Prevention
Coalition, Organic Consumers Association, and Family Farm Defenders.127
Citing scientific literature, the petitioners claim that rBST milk is, in fact,
abnormal.128 The petitioners claim rBST milk has: 1) reduced casein,129 2) different fatty acid composition, 3) higher thyroid hormones, 4) antibiotic residue
from treatment of mastitis,130 and 5) more frequent pus cells due to mastitis.131
Additionally, the petition‘s greatest emphasis is on insulin growth factor (IGF-1).
IGF-1 is a protein hormone that is statistically higher in rBST-treated milk.132
When the FDA approved Posilac, ―not much was known about the hormone.‖133
However, petitioners assert that now, some fourteen years later, ―[i]ncreased levels of IGF-1 have been shown to increase risks of breast cancer by up-to seven
fold in 22 publications. . .risks of colon cancer in 16 publications. . .and prostate
cancer in 10 publications. . . .‖134 Many of the publications cited were published
after 1994, though the petition does not specifically claim that they link rBST in
milk and human cancer rates.135
To date, the FDA has taken no action on the petition. When and if it
does, as Amestoy and Stauber held years ago, action must be based on scientific
evidence, not consumer preferences. In the absence of scientific evidence of
material differences in rBST-free and conventional milk attributable to Posilac, it
is unlikely that the law would permit revocation of Posilac or require cancer-risk
warnings. Rather than waiting for the FDA outcome and relying on FTC to
counsel wayward dairies, the rBST controversy has moved to the states.

_________________________
126.
Petition for Labeling of Products Produced with Posilac, supra note 3, at 1.
127.
Id.
128.
See generally id.
129.
Id. at 2. Casein is a protein that comes from milk‘s reaction with rennet (Enzymes
used to digest milk) resulting in the milk separating into cords and whey. Casein is used in cheese,
paint, and plastic.
130.
See Stauber v. Shalala, 895 F. Supp. 1178, 1184-85 (W.D. Wis. 1995) One way a
consumer can avoid most antibiotic residue is to purchase USDA organic milk.
131.
Petition for Labeling of Products Produced with Posilac, supra note 3, at 3.
132.
See id.
133.
See Stauber, 895 F. Supp. at 1185 (noting that ―defendants have done no long term
studies on the effects of increased levels of IGF-1 on human health.‖).
134.
Petition for Labeling of Products Produced with Posilac, supra note 3, at 3.
135.
Id. at 3-8.
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V. COMMERCIAL SPEECH, ROUND TWO: CURRENT LEGISLATION AND
RULEMAKING
Four states considered further specific guidance on rBST-free milk labels
in 2008: Indiana,136 Ohio,137 Kansas,138 and Pennsylvania.139 All four state actions
are similar. Indiana and Kansas would ban any dairy product claim related to
composition that lab analysis could not confirm or claims supported only by affidavits or testimonials.140 Pennsylvania bases its rBST mislabeling review on
―the entirety of the particular label under review.‖141 Ohio goes one step further
by specifically barring compositional claims such as ―No Hormone,‖ ―Hormone
Free,‖ ―rBST-free,‖ ―rbGH-free,‖ and ―bST Free‖ and classifying such claims as
―false and misleading.‖142 While these initiatives are largely consistent with the
1994 FDA compliance guidelines for rBST, one is much more specific (and restrictive).
The Ohio rule is a radical enough departure from the 1994 FDA Guidance, that the International Dairy Foods Association is seeking an injunction
against it.143 Specifically, the regulation only permits the words ―this milk is from
cows not supplemented with rBST.‖144 It then goes on to require a contiguous
disclaimer, rather than use of an asterisk to make the disclaimer elsewhere on the
packaging (as is the current prevalent practice).145 Finally, the Ohio rule also
mandates font size, color, and type to match the permitted statement.146 The rule
_________________________
136.
See H.B. 1300, 115th Gen. Assem., 2d Reg. Sess. (Ind. 2008).
137.
Ohio Emergency Rule, Dairy Labeling, 901:11-8-01 (May 22, 2008).
138.
See S.B. 595, 2008 Sess. (Kan. 2008).
139.
Pa. Dep‘t. of Agric., Milk Labeling Standards 2.0.1.17.08 (proposed Jan. 17, 2008)
The proposed standard was postponed by Pennsylvania Governor Rendell due to consumer demands for continued rBST-free labels.
140.
See S.B. 595, 2008 Sess. (Kan. 2008); H.B. 1300 115th Gen. Assem., 2d Reg. Sess.
(Ind. 2008).
141.
Pa. Dep‘t. of Agric., Milk Labeling Standards 2.0.1.17.08 (Proposed Jan. 17, 2008).
142.
Ohio Emergency Rule, Dairy Labeling, 901:11-8-01 (May 22, 2008).
143.
Complaint at 1, Int‘l Dairy Foods Ass‘n v. Boggs, No. 08-cv-00628-JLG-NMK,
supra note 6.
144.
Ohio Emergency Rule, Dairy Labeling, § 901:11-8-01 (B) (May 12, 2008) (stating
―A dairy label which contains a production claim that ‗this milk is from cows not supplemented
with rbST‘ (or a substantially equivalent claim) will be considered misleading on the basis of such
language, unless. . .‖ and the rule goes on to require documentation and is accompanied ―in the
same label panel, in exactly the same font, style, case, size and color as the foregoing representation, the following contiguous additional statement (or a substantially equivalent statement): ‗The
FDA has determined that no significant difference has been shown between milk derived from
rbST-supplemented and non-rbST-supplemented cows.‘‖).
145.
Id.
146.
Id.
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is more restrictive than any other state or federal rBST-free label guidance. Ohio
argues that its labels are necessary to avoid consumer confusion.
Boggs is the mirror image of Amestoy the − Vermont case finding mandatory disclosure of rBST use an unconstitutional commercial speech restriction.
While in Amestoy farmers fought for their right to remain silent about production
methods,147 today farmers are fighting for their right to announce production
methods. Unlike Vermont‘s desire to make sure consumers knew if milk contained rBST, Ohio wants consumers to know that rBST milk is no different from
conventional. However, the IFDA argues that the Ohio rule cannot survive its
challenge because there is no evidence that the current labels, compliant with the
1994 FDA Guidance, are false and misleading.148 IFDA‘s argument is a good
one because absent consumer surveys showing confusion or an FTC finding
(which we already know was not forthcoming) of false and misleading, Ohio has
little evidence to support its position.
Consumer confusion is not a substantial state interest in the commercial
speech context.149 Thus, even if the Court is persuaded that the current labels are
false and misleading, Ohio‘s rule will still have to survive Central Hudson analysis. This will be difficult without more compelling disclosure of the government‘s motives. As the litigation currently stands, the IFDA rests on the press
releases from the Ohio Department of Agriculture (ODA) that point to consumer
confusion as the ―substantial interest‖ that justifies the new rule. Absent better
evidence of consumer confusion, this is unlikely to constitute a ―substantial interest‖ – even if it did, Amestoy calls into question whether any regulation solely
based on consumer concern can survive Central Hudson analysis.150
Obviously, Ohio has an additional concern – one that it should not be
afraid to herald – the dairy industry. The interests here are two-fold: allowing
farmers to maximize their production and indirectly, promoting the acceptance of
Posilac, which is after all, an FDA-approved drug. It is safe for animals (though
it is not a zero tolerance standard) and safe for human consumption – or at least
that is what the science showed in 1994. Since conventional milk is also cheaper,
Ohio‘s rule could also be viewed as protecting the consumer by supporting those
farmers who choose to use rBST, and thus produce cheaper milk. In this time of
rising food costs such a goal is substantial.
_________________________
147.
Compare Int‘l Dairy Foods Ass‘n v. Amestoy, 92 F.3d 67, 67 (2d Cir. 1996), with
Complaint at 22, Int‘l Dairy Foods Ass‘n v. Boggs, No. 2:08-cv-00628-JLG-NMK, supra note 6.
148.
See Complaint at 22, Int‘l Dairy Foods Ass‘n v. Boggs, No. 2:08-cv-00628-JLGNMK, supra note 6.
149.
Int’l Diary Foods Ass’n, 92 F.3d at 74 (citing Riley v. Nat‘l Fed. of the Blind, 487
U.S. 781, 797-98 (1988)).
150.
See Int’l Diary Foods Ass’n, 92 F.3d at 74.
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Boggs also raises commerce clause issues as well as administrative law
concerns relating to the enactment of an emergency rule. The court has scheduled the parties to submit summary judgment arguments in August 2008. Those
filings will determine whether Ohio can be more restrictive than the FDA guidance, but it will not resolve the underlying labeling issue.
The convergence of the FTC labeling complaint, FDA petition to withdraw Posilac approval, and state action against rBST-free labels is troubling.
This type of consumer-driven controversy is not supposed to happen. Consumers
are supposed to accept the FDA‘s rBST safety ruling as clear proof that it is safe
for human consumption and that its risk to animal welfare is acceptable.151 Consumers are supposed to buy organic milk if they want milk free of genetically
engineered materials – not demand that conventional milk come clean. Further,
industry – whether producers or manufacturers of products that support producers
– is supposed to respond to market forces by changing the product offered, not
seeking legislation against the consumer. The activity surrounding rBST in all
parts of the milk market should indicate to government regulators either that consumers are truly misinformed or that government approval of rBST was a mistake.
VI. GOT SOLUTIONS? REGULATORS AND INDUSTRY SHOULD
The history of rBST, and the fact that it is repeating itself, should prompt
lawmakers, regulators, and industry to move beyond the current regulatory
schemes. Specifically, there should be an effort to understand consumers‘ perceptions of rBST, similar to the evidence presented in the Tyson case.152 Next,
there should be study of what label design is most effective for consumers and
producers. Once these two steps are taken, lawmakers can determine how to
modify the FDA guidance and similar state provisions. One method might be a
federal decision to abandon the guidelines and rely on the USDA organic symbol
to help consumers find rBST-free milk. Another solution is to devise an rBSTfree symbol similar to the USDA organic logo.
Altering milk labels will not be an easy task and will face opposition.
Unless the FDA takes the bold step of reviewing rBST safety, consumer concerns
about rBST milk will remain. In the FDA‘s defense, without compelling scientific evidence that rBST approval was a mistake there is little that they can do to
remove it from the milk supply. As state regulators and producers rigidly adhere
to rBST‘s safety determination, consumers seem to have grown more distrustful
_________________________
151.
See Stauber v. Shalala, 895 F. Supp. 11178, 1184 (W.D. Wis. 1995) (stating that the
standard is acceptable risk, not zero tolerance).
152.
See generally Sanderson Farms v. Tyson, 547 F. Supp. 2d 491, 491 (D. Md. 2008).
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of rBST. Since the market for rBST milk has rapidly decreased, wholesalers and
retailers alike demand farmers discontinue rBST use. The existence of a market
for ―rBST-free milk,‖ − that is not organic milk, but not conventional milk −
should tell regulators that milk labels are not providing the best information to
consumers. A potential middle ground exists in the creation of an rBST-free
symbol that is not accompanied by text.
The activity surrounding rBST in all parts of the milk market should indicate to government regulators that there is a significant information imbalance
that affects both producers and consumers.153 To resolve the controversy, all parties need to understand exactly what consumers want and what they understand
about rBST. While generalizations can be made and interest groups can advocate
for the generic ―consumer,‖ the parties should understand that consumer survey
data is the most reliable way to design rBST-free labels. Unless there is better
understanding of how consumers perceive the information on milk labels, the
controversy will continue.

_________________________
153.
Cf. Press Release, Tyson Foods, Tyson to Withdraw Qualified Raised Without Antibiotics Chicken Label; Company Calls for Public Process to Address Regulatory Confusion (June
2, 2008), http://www.tyson.com/corporate/press room/viewarticle.aspx?id=2955&print=true. Tyson stood to make millions on its ―raised without antibiotics‖ poultry label claim. Rather than
spend millions fighting about the labels in court or with the USDA, on June 3, 2008, Tyson foods
announced that it was withdrawing its qualified ―Raised without Antibiotics Label.‖ The company‘s press release declared:
We still support the idea of marketing chicken raised without antibiotics because we
know it‘s what most consumers want. . . .[h]owever,. . . to preserve the integrity of our
label and our reputation as a premier company in the food industry, we believe there
needs to be more specific labeling and advertising protocols developed to ensure the rules
are clear and application of the rules is equitable.
While the Tyson antibiotic label litigation undoubtedly carried costly legal expenses and negative press that Tyson chose to withhold production information was in hopes of clearer regulation is
not an optimal outcome for consumers (or producers).

